
VEGFR-3-IN-1
CAS No. 2756668-73-0
VEGFR-3-IN-1( —— )
Catalog No. M36479 CAS No. 2756668-73-0
VEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 73 | Get Quote |
![]() ![]() |
5MG | 107 | Get Quote |
![]() ![]() |
10MG | 180 | Get Quote |
![]() ![]() |
25MG | 348 | Get Quote |
![]() ![]() |
50MG | 569 | Get Quote |
![]() ![]() |
100MG | 894 | Get Quote |
![]() ![]() |
500MG | 1782 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameVEGFR-3-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionVEGFR-3-IN-1 is a novel, potent, and selective VEGFR3 inhibitor with an IC50 of 110.4 nM.
-
DescriptionVEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth.
-
In VitroVEGFR-3-IN-1 (compound 38k) exhibits a significantly higher antiproliferative activity on MDA-MB-231 and MDA-MB-436 cells than 10 (IC50 > 50 μM), with IC50 values of 2.22 and 3.50 μM, respectively.VEGFR-3-IN-1 markedly suppresses the phosphorylation of VEGFR3 and its downstream proteins in a dose-dependent manner.Cell Viability Assay Cell Line:MDA-MB-231 and MDA-MB-436 cells Concentration:100 nM Incubation Time:48 hours Result: Exerted antimigration and antiproliferative activities through targeting VEGFR3 in MDA-MB-231 and MDA-MB-436 cells.Western Blot Analysis Cell Line:HDLEC cells Concentration:10-500 nM Incubation Time:Result: Antilymphangiogenic activities of VEGFR-3-IN-1 by suppressing the expression of VEGFR3.
-
In VivoVEGFR-3-IN-1 (50, 25 mg/kg; p.o.) reduces the tumor volume, and displays the strongest inhibitory activity in mice, with a growth inhibition rate of 61.9%.VEGFR-3-IN-1 (10 mg/kg; p.o.) treatment shows the Cmax, AUC0-t , AUC0-∞ and t1/2 values of 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.Animal Model:Nude mice (carrying xenografted BC)Dosage:50 mg/kgAdministration:P.o.;once Result:Reduced the tumor volume, and displayed the strongest inhibitory activity in mice.Animal Model:Sprague-Dawley (SD) rats Dosage:10 mg/kg Administration:P.o. (Pharmacokinetic Analysis)Result:The Cmax, AUC0-t , AUC0-∞ and t1/2 were 420 ng/mL, 9219 ng h/mL, 12304 ng h/mL and 16 hours, respectively.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2756668-73-0
-
Formula Weight616.1
-
Molecular FormulaC29H29ClF3N7OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (20.29 mM; ultrasonic and warming and adjust pH to 6 with HCl and heat to 60°C )
-
SMILESC(NC1=CC(C(F)(F)F)=C(Cl)C=C1)(=O)N2CCN(C3=C4C(SC(=C4)C5=CC=C(C=C5)N6CCN(C)CC6)=NC=N3)CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li Y, Yang G, et al. Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer. J Med Chem. 2021;64(16):12022-12048.?
molnova catalog



related products
-
Bevacizumab
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
-
Semaxinib
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor.
-
SCR-1481B1
SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor.